Plasma GFAP: Another Biomarker for Alzheimer Disease?

Plasma glial fibrillary acidic protein levels may be useful in discriminating amyloid beta status throughout the Alzheimer disease continuum.

Plasma glial fibrillary acidic protein (GFAP) levels, an indicator of astrogliosis, could be a biomarker for Alzheimer disease (AD). In this study, researchers analyzed cross-sectional data from three international cohorts (n=187–384 participants; mean age, 61–65 years; 59%–62% female) to determine plasma GFAP levels throughout the AD continuum and to compare them with GFAP levels in the cerebrospinal fluid (CSF). Participants were classified as cognitively unimpaired (CU) or having mild cognitive impairment (MCI) or AD dementia and also categorized as amyloid-beta positive (Aβ+) or amyloid-beta negative (Aβ−) based on amyloid imaging or CSF studies. Other biomarkers analyzed included CSF Aβ42/40 levels, phosphorylated tau-181 (p-tau181), n…

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Plasma GFAP: Another Biomarker for Alzheimer Disease?

Topics

Reviewing Author